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OPINION STATEMENT 
 
Gliomatosis cerebri (GC) is an intriguing disease for several reasons. First, it is almost 
impossible to draw the border between GC and diffuse gliomas. In this regard, GC 
could represent the most invasive form of diffuse gliomas. Second, both in terms of 
histological grading and clinical course, GC is a heterogeneous disease, ranging from 
rapidly evolving to slowly and somewhat indolent forms. 
Because of the extensive spread of the disease, surgery –outside a biopsy for 
diagnosis- is rarely indicated in gliomatosis cerebri. Therapeutic options include 
radiotherapy, generally involving the whole brain, and chemotherapy with 
temozolomide or nitrosoureas. Due to the rarity of the disease, no trial comparing 
these two modalities has been undertaken so far. Decision is therefore based on 
small retrospective non comparative studies and expert opinions. On one hand 
there is a rationale to postpone the whole brain radiotherapy because of late 
neurotoxicity, but on the other hand there is also the risk that an aggressive disease 
evolves to intracranial hypertension making the radiotherapy hazardous or even 
impossible. As a consequence the patient would lose the opportunity to receive a 
potentially effective treatment. In this decision, the evaluation of histological data 
together with clinical and radiological features, performance status, and molecular 
profile may be of help.  
Because radiotherapy usually involves large volumes of the brain, chemotherapy is 
generally preferred up-front in patients with a slowly evolving disease. Conversely, 
in patients with rapidly (ie over few weeks) evolving disease with neurological 
deficits or when histological features of glioblastoma are evident, whole brain 
radiotherapy (45 Gy with 1.8 Gy fractions), alone or associated with concomitant 
temozolomide, is often preferred.  
The value of advanced MRI and PET techniques to predict outcome and monitoring 
the treatment still remains to be defined. 
 
INTRODUCTION 
 
Definition 
According to WHO 2007, gliomatosis cerebri (GC) is defined as “diffuse glioma, 
usually astrocytic, growth pattern consisting of exceptionally extensive infiltration of 
a large region of the CNS with the involvement of at least three cerebral lobes, 
usually with bilateral involvement of the cerebral hemispheres and/or grey matter, 
and frequent extension to the brain stem, cerebellum and even the spinal cord”.  In 
addition, an oligodendroglial phenotype can be present. GC is considered as a grade 
III tumor by WHO classification. 
GC includes “de novo” gliomatosis (primary gliomatosis); conversely, the term 
“secondary gliomatosis” refers to a diffuse pattern of growth of a preexistent focal 
glioma.  
GC has been for a long time considered as a rare and very aggressive tumor, with 
most cases diagnosed at autopsy[1]. The widespread use of MRI clearly shows that 
the incidence has been underestimated in the past and also reveals a wide 
heterogeneity in the outcome with a substantial number of indolent and slowly 
evolving cases. GC has been reported at any age (from infant to elderly patients, but 
clearly neonatal forms correspond to a different entity), with a peak incidence 
between 40-50 years and a slightly higher prevalence in males[2-5]. 
Because of the rarity of the disease, the majority of the publications are small 
retrospective case series or case reports: thus, many aspects of the disease remain 
to be clarified. 
 
Clinical aspects 
Clinical presentation is variable, depending on the structures involved. In the most 
recent series, seizures were more common than focal neurological deficit and 
intracranial hypertension[5-8]. When isolated, seizures often reveal a slowly 
evolving GC. In some patients the presentation consists of a status epilepticus. In 
contrast, older studies (including patients mainly from the CT-era) have indicated 
headache and intracranial hypertension as the most common presenting symptoms 
corresponding usually to aggressive and rapidly evolving GC [9-11]. GC can be 
revealed by isolated neurocognitive deficits and personality changes mimicking 
dementia [12] or by gait disturbance, cerebellar signs, cranial nerve palsies in case of 
an infratentorial involvement. GC can be revealed by unusual symptoms such as 
Parkinsonian syndrome when involving basal ganglia [13], blurred vision due to optic 
nerve infiltration [14] or spinal symptoms in case of spinal cord involvement.  
 
Neuroimaging 
CT shows only subtle ill-defined low density or even isodensity diffuse brain 
swelling, discrete ventricular asymmetry, but it does not adequately reveal the true 
extent of the disease, and may even be considered normal in a minority of cases[4]. 
MRI has a greater sensitivity, showing diffuse T2/FLAIR hyperintensities of the 
involved cerebral structures; mass effect may be absent or minimal, while in up to 
one third of patients small and patchy areas of contrast enhancement are present. 
Such features are non-specific and patients are often misdiagnosed with other 
neurological diseases, such as CNS inflammatory diseases, vasculitis, encephalitis, 
leucoencephalopathies, especially when there is no obvious mass effect[4]. 
Nevertheless, asymmetrical or heterogeneous distribution of  hyper-intense areas 
on FLAIR/T2 sequences, mild hemispheric swelling, collapse of a ventricular horn, 
thickening of the corpus callosum, involvement of the anterior white commissure, 
loss of clear delineation between white and gray matter are all suggestive of GC 
[11,15-19]. Most of the GC predominate in the white matter; less frequently GC 
involves predominantly grey matter and shows an abnormally thick cortex or 
bilateral involvement of basal nuclei and thalamus[19] (Figure 1). During the course 
of the disease, another third of patients develop contrast-enhancing lesions, 
sometimes with important mass effect.  
Advanced neuroimaging can be of help to manage patients with GC. Compared with 
low grade gliomas (whose MRI pattern can be similar), GC often displays lower 
choline levels and higher myoinositol and creatine levels [20-22]. Metabolic 
abnormalities may be detected in unaffected areas of the brain [23]. Diffusion 
tensor imaging may visualize the relationships between fiber tracts and the 
infiltrating tumor [24] or appreciate the integrity of the white matter structure [25]. 
Cerebral blood volume is usually normal in GC [26], while PET with aminoacids may 
show focal hypermetabolism [27].  
 
Diagnosis 
GC simulates a wide range of diseases [4,28]. Due to the relatively low specificity of 
MRI findings, histological confirmation is mandatory, and shows a glial proliferation 
invading an otherwise normal brain parenchyma (Figure 1). Identification of tumor 
cells may be difficult, and immunohistochemistry may be very useful by showing a 
proliferating population with elevated Ki67 (Figure 1), and by identifying, in case of 
IDH1 mutated GC, single positive cells [29] (Figure 1). However, one must keep in 
mind that the biopsy may undergraduate the glioma aggressiveness, and this is 
particularly true in the case of GC. Therefore, the histological grading must be 
matched with clinical and radiological features. 
 
 
Prognostic factors 
Some studies, mostly retrospective, have tried to define clinical and molecular 
factors predicting the outcome.  
Better outcome is associated with low grade histology, young age and good 
performance status[4,7,30,31]. It is also likely that patients with oligodendroglial 
phenotype, 1p19q codeletion, MGMT promoter methylation and IDH1 mutation 
have a better survival and better response to chemotherapy[29-31]. GC with 
prominent white matter involvement seems also to display a better outcome and 
higher response to chemotherapy: these cases have also a better performance 
status and are more frequently oligodendroglial tumors with 1p19q codeletion[19]. 
Conversely, grey matter gliomatosis is characterized in children by a very poor 
survival [32].  However, these data need to be confirmed by independent studies. 
Contrast enhancement was not consistently associated with outcome [7, 31]. 
MRS could be used as a predictor of response to therapy or of progression [33-35]). 
The choline/creatine index on MRS has been reported to inversely correlate with 
survival [36]. 
 
 
TREATMENT 
 
There is no standard treatment for GC, and the therapeutic choice should be 
tailored to the patient characteristics. In addition, GC is an extremely heterogeneous 
entity, and the indications are based on small retrospective non comparative 
studies, case reports and experts opinion, ie a low level of evidence (class IV). An 
additional difficulty is due to the fact that biopsy may underestimate tumor 
aggressiveness: therefore, the histology must be matched with clinical and 
radiological data. Although there is no indication on the respective efficacy of 
chemotherapy vs radiotherapy, all data suggest that both regimens are effective up-
front in GC. This prompted several groups to propose chemotherapy as up-front 
treatment 
 
 
Surgery 
Given the extensive spread of the disease, patients with GC are rarely offered 
surgery outside of diagnostic purposes. In some cases a surgical decompression is 
needed to relieve local mass effect. There are no data evaluating the impact of 
surgery in GC both at the time of diagnosis or at recurrence. A retrospective study 
found no significant advantage both in terms of disease progression and overall 
survival for partial resection compared to biopsy[37] . 
 
Radiotherapy 
Radiotherapy (RT) has been for long time the treatment of choice of GC. Available 
data are based on small retrospective and heterogeneous studies in terms of 
inclusion criteria. 
Cozad et al. (1996) published 3 cases treated with RT, with no clinical or radiologic 
benefit[38]. Elshaikh et al (2002) reported a median survival of 11.4 months in 8 
patients treated with RT alone (median dose 55.4 Gy) with a clinical response in 3 
patients[39].  
A series of 30 GC, patients were treated from 1980 to 1998 at MD Anderson with 
localized (22 patients) or whole-brain (8 patients) radiotherapy (median dose 54.9 
Gy; range 50-66 Gy): clinical improvement was observed in 70% and radiological 
partial response in 33% of patients, median PFS was 10 months and median OS 18 
months[37]. Twenty-two patients were treated at University of California from 1990 
to 2000: median OS was 28 months for patients treated with RT alone [31].  
A retrospective review comparing patients receiving radiotherapy with patients not 
receiving radiotherapy did not reveal a prolongation of survival for the radiotherapy 
group [4]. Moreover, the survival after salvage radiotherapy in patients failing 
primary chemotherapy is only of few months [40]. In contrast, a series of 54 patients 
from the Mayo Clinic found radiotherapy strongly associated with better prognosis, 
but selection bias could be present in this retrospective study [41]. 
 
 
 
 
Chemotherapy   
In the last years chemotherapy has been increasingly used as initial treatment with 
the aim to postpone large field radiotherapy that may result in a non negligeable 
risk of neurotoxicity in long surviving patients.  
The studies employing chemotherapy as upfront treatment are reported in Table 1. 
In the early studies the PCV (Procarbazine-CCNU-Vincristine) regimen was the most 
used, and has been then replaced by temozolomide: the latter is better tolerated 
and can be delivered for long periods (2 years or more), whereas lung toxicity limits 
the use of CCNU to one year treatment. Nevertheless, the efficacy of PCV seems at 
least equal to TMZ[7,42]. A recent study performed in low grade gliomas found a 
prolonged decrease of tumor volume during a median time of 3 years after the end 
of the PCV regimen [43,44].  
With PCV, Herrlinger et al (2002) reported a stabilization lasting 6 months in 4/6 
patients[45]. Glas et al (2008) observed a median progression-free survival of 16 
months and a median overall survival of 37 months among 12 patients[8].  
Among the 17 patients treated with PCV in the ANOCEF study [7], objective clinical 
improvement was observed in 41% and a radiologic response (partial and minor 
response) in 31.2%, versus 30.5% and 24% for the 45 patients treated with 
temozolomide. Importantly, the response was often delayed occurring after 3 to 9 
months and was maximal at 6 to 18 months after the start of treatment. No 
significant difference was seen between PCV-treated and TMZ-treated patients in 
either PFS (15.8 months vs 16 months) or OS (25.6 months vs 26.4 months). The PFS 
and OS were significantly longer for oligodendroglial tumors (21.2 and 33.9 months) 
than for mixed and astrocytic tumors (6.2 and 11.1 months).  
In a retrospective compilation of published GC cases, the use of chemotherapy 
(mainly PCV) was associated with better survival, but again this may reflect a 
population bias. The median survival of chemotherapy-treated patients varied from 
11 months for astrocytic and mixed tumors to 36 months for oligodendroglial 
tumors[4]. 
Patients with 1p/19q codeletion had a higher response rate (88% vs 25%), higher 
PFS (24.5 vs 13.7 months) and overall survival (66.8 vs 15.2 months). Similarly, 
patients with unmethylated MGMT promoter tended to have a shorter PFS and a 
higher rate of progressive disease [30]. 
Levin et al (2004) treated with TMZ 11 patients and documented an objective 
response in 45%, a median time to tumor progression of 13 months and a 
progression-free survival of 55% at 12 month[3]. In a case series of elderly patients 
(aged 70-83 years) temozolomide yielded an encouraging survival of 16 months[46]. 
A retrospective AINO study [47] has compared in 51 patients the use of 
temozolomide in the upfront setting or at recurrence, respectively. Responses were 
similar for patients treated upfront (24.5%) or at recurrence (22.7%), and prevailed 
among patients with 1p/19q codeletion (55.5% vs 12.5%). A significant clinical 
improvement was observed in 31-33% of patients. Overall survival of whole series 
was 15 months. 
The efficacy of primary PC chemotherapy has been recently confirmed in a 
prospective phase II trial by the German group (NOA-5), that has reported a failure-
free survival at 8 months (primary end-point) of 50.3%, a median PFS of 14 months 
and a median OS of 30 months[40].  
A recent retrospective study found a benefit for adjuvant chemotherapy (PCV or 
BCNU) after radiotherapy (24 months compared with 13 months for radiotherapy 
alone)[48].  
The data on the combination of radiotherapy and chemotherapy are scarce[49]. A 
recent review on 61 patients, collected from the literature, found no differences in 
the rate of response between TMZ alone (26.2%), WBRT alone (26.2%) and 
concomitant TMZ and WBRT (20%)[50]. 
 
Considering the risk of late neurotoxicity with radiotherapy, we recommend to use 
up-front chemotherapy in the majority of the GC. GC with areas of glioblastoma 
should be treated with radiotherapy (with reduced dose owing to the large volume) 
combined with temozolomide[51]. Considering that the biopsy may underestimate 
the real grade of the tumor, radiotherapy possibly with temozolomide may be 
applied to clinically aggressive GC. In the attempt to propose a more aggressive 
treatment and to postpone the radiotherapy, an ongoing phase II trial performed by 
AINO investigates the role of dose-intensification of temozolomide in primary 
gliomatosis cerebri.  
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Legend to the figure: 
A- An example of a grey matter GC involving mostly basal ganglia (top: T1 with 
gadolinium; Bottom: Flair). B- An example of white matter gliomatosis cerebri with 
excellent response to temozolomide (top: before treatment; bottom, after three 
temozolomide cycles, FLAIR). C- HE of a GC invading the corpus callosum. D- Ki67 
labelling of the same sample. E- Ki67 labelling showing proliferating tumor cells 
invading the cerebellum. D- IDH1R132H labelling (Courtesy of Dr Karima Mokhtari) 
 
 
 
